Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in Healthy Volunteers
Trial status:Recruitment Complete
Study Identifier:
BNT164-01
ClinicalTrials.gov Identifier:
EudraCT Identifier:
Sponsor:
The sponsor of a clinical trial is the company, institution or individual that takes responsibility for initiating, managing, and/or financing a clinical investigation. BioNTech collaborates with other pharmaceutical companies or institutions (collaborators) to develop certain new medicines. In particular cases BioNTech's collaborators are leading specific clinical trials and are acting as sponsors accordingly.
BioNTech SE
Recruitment Complete
Trial details
Medical Condition
Study Drug
Phase
Phase 1
Sex
Female & Male
Age
18 - 55 Years
Estimated Trial Date
Apr 2023 - Sep 2024
Protocol summary
This randomized, placebo-controlled, double-blind, safety and dose-finding Phase Ia trial will evaluate four dose levels of the BNT164 investigational vaccines (BNT164a1 and BNT164b1) to select a safe and tolerable dose in a three-dose schedule.
Trial locations
Location
Status
Location
emovis GmbH
Berlin, Germany, 10629
Status
Location
CRS Clinical Research Services Berlin GmbH
Berlin, Germany, 13627
Status
Location
CRS Clinical Research Services Mannheim GmbH
Mannheim, Germany, 68167
Status